TuHURA Biosciences (NASDAQ:HURA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of TuHURA Biosciences (NASDAQ:HURA) from a sell rating to a hold rating in a report released on Saturday morning.

A number of other research analysts have also recently weighed in on HURA. Maxim Group dropped their price objective on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, TuHURA Biosciences currently has a consensus rating of “Buy” and an average target price of $10.33.

TuHURA Biosciences Trading Down 2.0%

HURA opened at $1.94 on Friday. The stock’s 50-day moving average price is $2.27 and its 200 day moving average price is $2.53. TuHURA Biosciences has a 12-month low of $1.56 and a 12-month high of $6.90. The firm has a market cap of $99.44 million, a price-to-earnings ratio of -3.88 and a beta of -0.03.

TuHURA Biosciences (NASDAQ:HURA) last released its earnings results on Friday, November 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01.

Institutional Investors Weigh In On TuHURA Biosciences

Large investors have recently modified their holdings of the company. Suncoast Equity Management lifted its position in shares of TuHURA Biosciences by 4.4% during the 2nd quarter. Suncoast Equity Management now owns 104,409 shares of the company’s stock worth $233,000 after purchasing an additional 4,412 shares during the last quarter. Virtu Financial LLC acquired a new stake in TuHURA Biosciences in the third quarter valued at $26,000. JPMorgan Chase & Co. acquired a new stake in TuHURA Biosciences in the second quarter valued at $27,000. Intech Investment Management LLC purchased a new stake in TuHURA Biosciences during the 2nd quarter worth about $29,000. Finally, Invesco Ltd. purchased a new stake in TuHURA Biosciences during the 2nd quarter worth about $30,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.